Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its fourth-generation Halcyon radiotherapy platform. The Halcyon system is a circular rack radiotherapy platform designed to deliver efficient image-guided automated radiation therapy.- Flcube.com
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
